During the past decade, Centre d'Oncologie de Gentilly conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 18 clinical trials were completed, i.e. on average, 46.2% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 12 clinical trials were completed. i.e. 85.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre d'Oncologie de Gentilly" #1 sponsor was "ARCAGY/ GINECO GROUP" with 14 trials, followed by "Hoffmann-La Roche" with 13 trials sponsored, "Pfizer" with 4 trials sponsored, "Merck Sharp & Dohme LLC" with 3 trials sponsored and "UNICANCER" with 3 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre d'Oncologie de Gentilly" #1 collaborator was "Hoffmann-La Roche" with 3 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator and "Foundation Medicine" with 2 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Centre d'Oncologie de Gentilly" are "Breast Cancer" (6 trials), "Ovarian Cancer" (6 trials), "Colorectal Cancer" (3 trials), "Endometrial Cancer" (3 trials) and "Prostatic Neoplasms" (3 trials). Many other conditions were trialed in "Centre d'Oncologie de Gentilly" in a lesser frequency.

Most popular intervention types in "Centre d'Oncologie de Gentilly" are "Drug" (45 trials), "Biological" (9 trials), "Other" (7 trials), "Procedure" (4 trials) and "Radiation" (4 trials). Other intervention types were less common.

The name of intervention was led by "Docetaxel" (6 trials), "Paclitaxel" (6 trials), "Bevacizumab" (5 trials), "Pembrolizumab" (5 trials) and "Placebo" (5 trials). Other intervention names were less common.

The vast majority of trials in "Centre d'Oncologie de Gentilly" are 28 trials for "All" genders, 22 trials for "Female" genders and 7 trials for "Male" genders.

Currently, there are NaN active trials in "Centre d'Oncologie de Gentilly". undefined are not yet recruiting, 9 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in Centre d'Oncologie de Gentilly, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Centre d'Oncologie de Gentilly, 0 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".